Time for some good news, page-23

Fellow posters , If we can just put the poor communication from SE1 to one side and unpack the impact of Sharad's interview on our company.


I want to focus on this comments about rapidly scaling manufacturing, and securing funding to do this.

- If you are doing this, you are extremely confident you are going to market with NanoDX ( EUA etc. ), and you have significant demand for your product.

Where do Sensera fit within the NanoDX supply chain.

From our quarterly reports :

28 Jan / Quarterly Update
The customer for the SARS-CoV-2 detection sensor which has been discussed by the Company
previously can now be disclosed as NanoDiagnostics Incorporated (NanoDX). The two companies
have been in partnership for more than eighteen months having initially collaborated on a
Traumatic Brain Injury (TBI) sensor using a patented nanosensor technology platform to detect the
presence of biomarker proteins in the blood. This was awarded a breakthrough devices designation
by the Food and Drug Administration (FDA) and is the same platform and sensor used for the SARSCoV-2 solution.

. Sensera has secured a manufacturing agreement predicated on FDA approval, which will
be fully disclosed in the event that NanoDX receives the approval. Sensera management still
expects to ramp this product into material production levels.

26th Feb / Half-Yearly

The SARS-CoV-2 sensor developed in conjunction with NanoDx has progressed through the
R&D phase and the final product is now in the hands of NanoDx. The Group has engaged in a material agreement that will
be fully disclosed once the sensor reaches FDA approval.

9th Dec / AGM Presentation Slides



So what does this mean :

We have a material contract, predicated on NanoDX EUA.
We have a patent on the sensor that drives NanoDX.
We thought we had $10M of business starting in Q3, back in early December.
- EUA was delayed due to cartridge issues. Launch now likely in the next few weeks, so delayed by a few months.

What we don't know, is what the volume that Sharad is indicating may now look like.
It had already gone from $3M indication 9 months ago to $10M 3 months ago.

Some of Sharad's comments :

CEOCFO: Where are you in the development and commercialization process?
Mr. Joshi: At this point, a large part of our development is behind us. Now we are manufacturing and developing manufacturing processes and scaling and improving our yield for those processes. As we improve those yields, we will be able to make more and more product. While the volumes for our ailments are very high, none are more urgent and important than that of COVID these days. We have a lot of interest and we are scaling tremendous amounts of manufacturing capability with our manufacturing partners to be able to bring this technology to more and more people.

CEOCFO: Are you seeking funding, partnership and investment now?
Mr. Joshi: Yes, we are. We have been very lucky to partner with some great people out there in terms of license fields to bring in non-dilutive funding to our company. We have also closed the Series C during 2020 and we also are seeking some additionally investment to really scale to a larger volume right now and we are very close to closing that so we can execute on the larger plans. The volumes of product that we are planning on building today are about well over a hundred times greater than the volumes we were seeking to develop and manufacture just a year ago.



NanoDiagnostics are planning for very large volumes on launch.
Sensera are a critical component supplier, and a key player in the launch.
IMO, there is every indication that the launch of NanoDX will be a company maker for Sensera.

GLTAH. IMO